The study included a substantial sample of 4017 people and showed a trend in decrease in the combined mortality, hospitalization for HF, nonfatal myocardial infarction, atrial fibrillation/flutter, type 2 diabetes mellitus, and New York Heart Association class ( P < 0.001) in the form of a win-ratio, which is being used by a number of newer trials.
← all excerpts
Coronary artery disease and heart failure: Late-breaking trials presented at American Heart Association scientific session 2023.
1
—
—